Loading quotes...
Forecast
The analysts' average price target is €19.17 (+112.53%). The median is €17.76 (+96.90%).
| Buy |
10 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » More on finance.yahoo.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -29.88m | 31.30% |
| EBITDA | -29.79m | 31.13% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €134.74m |
Number of shares | 13.62m |
52-week high/low | €15.10 - €4.38 |
| Dividends | No |
Beta | 1.41 |
P/E ratio | -2.38 |
PEG ratio | -0.03 |
P/B ratio | 3.81 |
P/S ratio | 0.00 |
Company profile
| Name | Immunic |
| CEO | Erik Lundgren |
| Employees | 100 |
